01.19.21

Bausch + Lomb Completes Enrollment Of First Phase 3 Study For NOV03 (Perfluorohexyloctane)

Source: Bausch + Lomb

11.24.20

Report: Dry Eye Treatment Devices Market Size Worth $400.8 Million By 2027

Source: Grand View Research, Inc.

11.24.20

Bausch Health Initiates Second Phase 3 Study for Investigational Treatment for Dry Eye Disease Associated With MGD

Source: Bausch Health Companies Inc.

10.22.20

Azura Ophthalmics Raises $20 Million for Registration Studies for Treatment of Meibomian Gland Dysfunction

Source: Azura Ophthalmics

10.01.20

New Company TearRestore Launches Reusable Heat Packs to Target the Meibomian Glands

Source: TearRestore

09.09.20

Sight Sciences Presents Additional Results of OLYMPIA Study of Signs and Symptoms of Dry Eye Disease Using TearCare

Source: Sight Sciences

05.28.20

New Alcon Program Aims to Help ECPs Tap Into Opportunities in the Dry Eye Market Amid COVID-19 Crisis

Source: Alcon

03.05.20

Alcon Launches Systane MyEyes to Increase Continuity of Care and Patient Retention Following iLUX MGD Treatment

Source: Alcon

06.13.19

First Subject Enrolled in Trial to Confirm Safety and Efficacy of TearCare Device for Dry Eye

Source: Sight Sciences

05.29.19

Quantel Medical Receives CE Mark for Dry Eye Treatment Platform Lacrystim IPL

Source: Quantel Medical

View more stories